We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BAX icon
201
Baxter International
BAX
$12.6B
– –
-21,269
Closed -$826K
BHC icon
202
CALL
Bausch Health
BHC
$1.69B
– –
-1,425
Closed -$12.3M
CERS icon
203
CALL
Cerus
CERS
$585M
– –
-477
Closed -$211K
CPRT icon
204
CALL
Copart
CPRT
$28.4B
– –
-14,392
Closed -$5.54M
ELV icon
205
CALL
Elevance Health
ELV
$83.7B
– –
-1,551
Closed -$12.7M
ELV icon
206
PUT
Elevance Health
ELV
$83.7B
– –
-1,551
Closed -$12.7M
GYRE icon
207
CALL
Gyre Therapeutics
GYRE
$668M
– –
-1
Closed -$352K
INSM icon
208
CALL
Insmed
INSM
$22.6B
– –
-1,875
Closed -$2.24M
IWM icon
209
PUT
iShares Russell 2000 ETF
IWM
$80.4B
– –
-5,000
Closed -$48.6M
LLY icon
210
CALL
Eli Lilly
LLY
$1.09T
– –
-10,238
Closed -$50.3M
LITS
211
Lite Strategy Inc
LITS
$33M
– –
-5,330
Closed -$833K
MYGN icon
212
CALL
Myriad Genetics
MYGN
$502M
– –
-4,126
Closed -$11.1M
MYGN icon
213
PUT
Myriad Genetics
MYGN
$502M
– –
-1,534
Closed -$4.12M
NBIX icon
214
CALL
Neurocrine Biosciences
NBIX
$18.4B
– –
-3,861
Closed -$5.17M
NBIX icon
215
PUT
Neurocrine Biosciences
NBIX
$18.4B
– –
-1,055
Closed -$1.41M
NSPR icon
216
InspireMD
NSPR
$32.1M
– –
0
– -$235K
PRGO icon
217
CALL
Perrigo
PRGO
$1.43B
– –
-2,240
Closed -$27.1M
PTN
218
Palatin Technologies
PTN
$13.7M
– –
-342
Closed -$257K
RMTI icon
219
CALL
Rockwell Medical
RMTI
$27.6M
– –
-44
Closed -$1.75M
RMTI icon
220
PUT
Rockwell Medical
RMTI
$27.6M
– –
-8
Closed -$304K
TLT icon
221
iShares 20+ Year Treasury Bond ETF
TLT
$43.1B
– –
-104,050
Closed -$11.5M
TXMD icon
222
TherapeuticsMD
TXMD
$23.8M
– –
-6,232
Closed -$944K
VNDA icon
223
Vanda Pharmaceuticals
VNDA
$310M
– –
-56,843
Closed -$607K
ZTS icon
224
CALL
Zoetis
ZTS
$32.5B
– –
-1,225
Closed -$3.78M
ZTS icon
225
Zoetis
ZTS
$32.5B
– –
-460,030
Closed -$14.2M
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.